Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

BOULDER, Colo., March 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 39^th Annual Cowen Health Care Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

A replay of the presentation will also be accessible under the "Investors/Investor Calendar" section of the website at www.arraybiopharma.com.  

About Array BioPharma 
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI^® (encorafenib) capsules in combination with MEKTOVI^® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600K mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi^® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo^® (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

BRAFTOVI^® and MEKTOVI^® are registered trademarks of Array BioPharma Inc. in the United States and various other countries. Vitrakvi^® is a registered trademark of Bayer AG. All trademarks are properties of their respective owners.

CONTACT:       
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
[email protected]

SOURCE Array BioPharma Inc.

Related Links

https://www.arraybiopharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED